Drug intelligence / Profile preview

RCI003

Development stage: Preclinical
Lead developer: Rudacure
Modality: Small Molecules

Overview

RCI003 is a small molecule drug candidate being developed by Rudacure for the treatment of psoriasis. It acts as a selective modulator of psoriasis-related target proteins associated with the Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel pathway. While the specific downstream proteins have not been publicly disclosed, the mechanism leverages the known role of TRPV1-related signaling in skin inflammation and psoriasis pathogenesis. As of early 2024, the program is in the discovery stage of development.

Targets

RAC1 (Rac family small GTPase 1)

Beyond the preview

Go deeper on RCI003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCI003.

Explore the full profile